Sugi Predict

Sugi Predict / Compounds / SCHEMBL2996261

SCHEMBL2996261

SCHEMBL2996261

COc1cc2[nH]cc(-c3cc4c(Cl)c(F)cnc4n3S(=O)(=O)c3ccc(C)cc3)c2nc1OC

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 1/20 0.34
▸ PIM2 Q9P1W9 1/20 0.34
▸ LMNA P02545 2/20 0.33
▸ EGFR P00533 2/20 0.33
▸ PTGDR2 Q9Y5Y4 2/20 0.32
▸ ALDH3A1 P30838 2/20 0.32
▸ TSHR P16473 1/20 0.32
▸ PKM P14618 1/20 0.32
▸ MET P08581 3/20 0.30
▸ KDR P35968 3/20 0.30
▸ MAP4K1 Q92918 1/20 0.30
▸ AXL P30530 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30
▸ HIF1A Q16665 1/20 0.30
▸ PTGS1 P23219 1/20 0.30
▸ PTGS2 P35354 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1749011 0.88 EGFR (0.40) EGFRPTGDR2PKMMETKDR
SCHEMBL2987041 0.87 PTGDR2 (0.36) LMNAEGFRPTGDR2ALDH3A1PKM
SCHEMBL2988252 0.86 LMNA (0.34) PIM1PIM2LMNAEGFRPTGDR2
SCHEMBL2991594 0.82 PTGDR2 (0.39) PIM1LMNAPTGDR2METKDR
SCHEMBL9987630 0.82 PIM1 (0.36) PIM1PIM2LMNAPTGDR2ALDH3A1
SCHEMBL9987566 0.81 PIM1 (0.31) PIM1PIM2SMN1; SMN2HIF1A
SCHEMBL2991242 0.81 PIM1 (0.35) PIM1PIM2LMNAPTGDR2ALDH3A1
SCHEMBL2995374 0.81 PIM1 (0.34) PIM1PIM2LMNAPTGDR2ALDH3A1
SCHEMBL13103441 0.81 L3MBTL1 (0.42) LMNAPTGDR2ALDH3A1TSHRMAPT
SCHEMBL2988487 0.81 PIM1 (0.35) PIM1PIM2LMNAPTGDR2ALDH3A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1799691-B1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2011-12-21 — — EP disclosed
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2010-10-07 — — US disclosed
US-7786114-B2 Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-08-31 — — US disclosed
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-02-21 — — US disclosed
EP-1799691-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2007-06-27 — — EP disclosed
WO-2006037875-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2006-04-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045561-A1 Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors BRSK2, KSR2, CDK2 PIM1 695/4885PIM2 607/4885LMNA 3052/4885
US-20100256141-A1 NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS BRSK2, KSR2, CDK2 PIM1 695/4885PIM2 607/4885LMNA 3052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.